Mahan Moshir
Gent, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Anti-C2-mediated complement inhibition prevents disease in a rat passive transfer model of myasthenia gravis.
Journal: Journal of translational autoimmunity
Published: June 19, 2026
Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 23, 2025
Optimization of the Cell-Based Assay Methodology to Study Degradation of Acetylcholine Receptors (Antigenic Modulation) by Antibodies From Myasthenia Gravis Patients.
Journal: Muscle & nerve
Published: August 05, 2025
Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models.
Journal: Human vaccines & immunotherapeutics
Published: March 03, 2025
Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys.
Journal: Journal of immunotoxicology
Published: February 13, 2025
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Journal: Cancer
Published: June 01, 2021
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 02, 2017
A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo.
Journal: mAbs
Published: October 19, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026